Drug Name:
Felodipine Rx
Generic Name and Formulations:
Felodipine 2.5mg, 5mg, 10mg; ext rel tabs.
Company:
Various generic manufacturers
Therapeutic Use:
Indications for Felodipine:
Hypertension.
Adult:
Take without food or with a light meal. Do not crush or chew. Initially 5mg once daily. Range 2.5–10mg once daily. Adjust at 2 week intervals; max 10mg daily. Elderly or hepatic dysfunction: initially 2.5mg once daily.
Children:
Not recommended.
Warnings/Precautions:
Heart failure. Hepatic impairment. Maintain good dental hygiene. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Pharmacological Class:
Calcium channel blocker (CCB) (dihydropyridine).
Interactions:
May increase metoprolol, tacrolimus levels. Potentiated by cimetidine. Increased bioavailability with grapefruit juice. Levels decreased with long-term anticonvulsants (eg, carbamazepine, phenytoin, phenobarbital), consider alternate antihypertensive therapy.
Adverse Reactions:
Peripheral edema, headache, flushing, dizziness, respiratory symptoms, weakness, cough, GI upset, gynecomastia; hypotension, tachycardia, syncope, MI, angina, gingival hyperplasia (rare).
Note:
Formerly known under the brand name Plendil.
How Supplied:
Contact supplier.
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Shifting Dynamics of Social Support After a Cancer Diagnosis
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |